Clinical pharmacology

Clinical pharmacology of CPT-11 and topotecan is now relatively well developed. Both can be absorbed orally, with topotecan bioavailability of 30-50%; both are widely distributed throughout the body, with cerebrospinal fluid topotecan concentrations 30-50% of simultaneous plasma concentrations.

Topotecan undergoes negligible metabolism. CPT-11 is in itself relatively inactive and must be converted by carboxylesterases to SN-38 that has potent topol inhibitory activity. SN-38 undergoes glucuronidation to inactive metabolite by uridine-diphosphosphate glucuronosylatransferase lAl and genetic polymorphism in the formation of SN-38 glucuronide has been proposed.

Topotecan is primarily eliminated by the kidneys, with evidence for renal tubular secretion. A linear relationship between creatinine clearance and clearance of both total topotecan and lactone form has been demonstrated. Approximately 20% of the total dose of CPT-11 is excreted unchanged in urine, whereas less than 1% is excreted as SN-38. Glucuronidation and biliary excretion appear to be principal mechanisms of elimination for SN-38.

Several mechanisms of resistance to topol inhibitors have been described in in vitro systems. These include:

♦ Factors that affect the stabilization of the topol-DNA complex

♦ Alterations in drug accumulation

♦ Decreased activation of CPT-11

♦ Decreased cellular content/activity of topol

♦ Mutations of the topo I enzyme

Little is know about mechanisms of resistance to CPT or its analogues in human tumours.

Was this article helpful?

0 0

Post a comment